SignalDailyGlobal signals. Global context.

Market Incident

Public · Developing

AI compiled from Infoway · 19 analyzed stories

Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance

Pfizer reported third-quarter 2026 revenues of $16.6 billion, relatively flat year-over-year operationally. Excluding its Comirnaty and Paxlovid products, revenue grew, and Pfizer raised its full-year 2026 guidance for both revenues and adjusted diluted earnings per share.

Published:

Updated:

What happened

Pfizer reported third-quarter revenue of $16.6 billion, roughly flat from a year earlier, while adjusted earnings per share were $0.87. It raised its 2026 revenue and adjusted earnings forecasts. The company also named Cecile Guegan as its next chief financial officer, effective November 1.

Global impact / market context

Higher sales from newer and acquired products, along with stronger demand for Eliquis and cancer drugs, helped offset falling COVID product sales. The raised forecast signals better expected results, but patent expirations, pricing, and successful delivery of its drug pipeline remain risks.

What to watch

  1. Check sales from newer and acquired products, which grew 32% in the quarter; continued growth would show whether they can offset weaker COVID product sales.
  2. Check demand for Eliquis and cancer drugs, which helped support the outlook; weaker demand could challenge the raised forecast.
  3. Check how Pfizer addresses patent expirations, pricing, and delivery of its drug pipeline, which the company identified as key drivers and risks.

Affected assets

  • Pfizer Inc. common stock

Evidence